Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JUNIPER: ND-L02-s0201 in Idiopathic Pulmonary Fibrosis
NCT03538301Phase 2Completed
- Sponsor
- Nitto
- Start
- Jun 2018
- Primary completion
- Aug 2022
- Modality
- Antisense DNA, Lipid-based Nanoparticles, Conjugated siRNA
- Countries
- 4
01
Overview
A Phase 2 trial of ND-L02-s0201 in idiopathic pulmonary fibrosis (IPF), sponsored by Nitto. Started Jun 2018; status: completed.
02
Drugs
ND-L02-s0201
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03538301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03538301.